SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Rexahn Pharmaceuticals, Inc. (RNN)

RNN RSS Feed
Add RNN Price Alert      Hide Sticky   Hide Intro
Moderator: beambe, DorianGray
Search This Board: 
Last Post: 5/27/2017 2:32:58 PM - Followers: 228 - Board type: Free - Posts Today: 0



   
 



   http://www.rexahn.com/cms/    

    http://finance.yahoo.com/q/ks?s=RNN

       

About

Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN) is a clinical stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. Rexahn’s clinical development programs directly target specific proteins that are selectively expressed in human cancer cells, resulting in increased efficacy and reduced toxicity. In preclinical studies these drug candidates are effective against multiple drug resistant cancers and have shown to increase the effectiveness of various FDA approved cancer treatments. Rexahn is also developing specific biomarker tests that will help identify which patients will be most responsive to its treatments. The Company’s nanotechnology-based drug delivery system has shown it can make FDA approved chemotherapy drugs more effective.

Our clinical development pipeline consists of three novel compounds:

Archexin® is a unique anti-sense drug candidate that specifically targets the cancer cell signaling protein Akt-1. Archexin is the only specific inhibitor of Akt-1 in clinical development. The activated form of Akt-1, which is involved in cancer cell growth, survival, angiogenesis, and drug resistance, has been shown to be present or elevated in more than 12 different human cancer cell lines, including pancreatic and renal cell carcinoma. By inhibiting Akt-1, Archexin has shown to inhibit the growth of human renal cell carcinoma cell lines and exhibit a longer survival benefit in the human renal cell carcinoma animal xenograft model. Thus, while Akt-1 is a very specific anti-cancer target, it may have broad therapeutic potential across multiple types of cancer.

RX-3117 is a next generation, orally bioavailable nucleoside analog that is activated (phosphorylated) by the enzyme Uridine Cytidine Kinase 2 (UCK2) and inhibits both DNA and RNA synthesis which induces apoptotic cell death of tumor cells. UCK2 is overexpressed in multiple human tumors, but has a very limited presence in normal tissues. This unique specificity for cancer cells may lead to an improved efficacy and safety profile in cancer patients. This profile differs from existing nucleoside compounds (such as the widely used chemotherapy gemcitabine), which are activated by the enzyme DCK which is expressed in both cancer cell and in normal healthy tissue leading to significant toxicities at therapeutic doses. RX-3117 has demonstrated broad spectrum anti-tumor activity against 100 different human cancer cell lines (including Non-Small Cell Lung Cancer (NSCLC), breast, ovarian, pancreas, colon, renal, brain, bladder, cervical) and efficacy in 17 different mouse xenograft models (including colorectal, non-small cell lung, pancreatic and renal cell carcinoma) superior to that of gemcitabine.

Supinoxin (RX-5902) is an orally administered, first-in-class, small molecule inhibitor of phosphorylated-p68 (P-p68). P-p68, which is selectively expressed in cancer cells and is absent in normal tissue, increases the activity of multiple cancer related genes including cyclin D1, c-jun and c-myc, and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been observed in solid tumors, such as melanoma, colon, ovarian and lung.

These clinical development programs are part of a growing oncology drug pipeline that consists of highly differentiated and exciting anti-cancer compounds.

Our strategy is to continue building a significant clinical development pipeline of innovative therapies that we will commercialize on our own or with other pharmaceutical partners. Rexahn’s powerful discovery engine and differentiated product pipeline provide the opportunity for a high value generating biopharmaceutical company.

 

 Rexahn  Pipeline

 

Management Team



Peter Suzdak, Ph.D.
Chief Executive Officer 

Dr. Peter Suzdak joined Rexahn Pharmaceuticals in February 2013. Dr. Suzdak has over 25 years of diverse experience, including several management positions, in the pharmaceutical industry. Most recently, Dr. Suzdak was Chief Scientific Officer of Corridor Pharmaceuticals, a company developing small molecule compounds to treat pulmonary and vascular disorders. Prior to Corridor Pharmacueitcals, he was co-Founder, Chief Executive Officer and Chief Scientific Officer of Cardioxyl Pharmaceuticals, a company focused on therapies for the treatment of cardiovascular disease. Previous to Cardioxyl Pharmaceuticals, he was President and Chief Executive Officer of Artesian Therapeutics, a company engaged in the development of small molecule therapeutics for cardiovascular diseases. Dr. Suzdak’s experience also includes his position as Senior Vice President of Research and Development of Guilford Pharmaceuticals, a company that developed therapeutics and diagnostics for neurological diseases and cancer, and as Director of Neurobiology for Novo Nordisk. Dr. Suzdak holds a Ph.D. in pharmacology and toxicology from the University of Connecticut.

Rick Soni, MBA
President and Chief Operating Officer

Rick Soni joined Rexahn in 2008 with over 20 years of sales, marketing, product planning and business development experience in the pharmaceutical industry. Prior to joining Rexahn, Mr. Soni held leadership roles at Otsuka America Pharmaceuticals, Inc., with responsibility for commercial development, corporate strategy and execution of licensing and acquisition of therapeutics, diagnostics and medical devices. Previously, Mr. Soni has held a variety of management positions at Novartis and Schering-Plough. Mr. Soni has a BS from the University of Wisconsin-Madison and an MBA from Fairleigh Dickinson University.

Tae Heum (Ted) Jeong, D. Mgt.
Sr. Vice President  and Chief Financial Officer

Dr. Jeong has been Chief Financial Officer of Rexahn Pharmaceuticals since 2002. He oversees all aspects of capital raising, accounting, operations, and corporate development for Rexahn. He is also responsible for investor relations, and played a key role in Rexahn’s 2008 listing on the New York Stock Exchange (NYSE) AMEX. For the past 16 years, he has extensive experience in venture capital and investment banking industry that includes role at Hyundai Venture Investment Corporation where he managed the Biotechnology investment team. Dr. Jeong holds a Doctor of Management from University of Maryland and an M.S. in Finance from Johns Hopkins University




ANALYST COVERAGE
 
Roth Capital Partners, LLC
      Joseph Pantginis, Ph.D.
646-358-1907

jpantginis@roth.com

Maxim Group, LLC
Echo He, MD, Ph.D.
212-895-3718

ehe@maximgrp.com

H. C. Wainwright & Co., LLC
Andrew Fein
212-356-0546

afein@hcwco.com   


INVESTOR RELATIONSThe Trout Group LLC
Tricia Truehart
(646) 378-2953
ttruehart@troutgroup.com

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
RNN
Current Price
Volume:
Bid Ask Day's Range
RNN News: Securities Registration Statement (simplified Form) (s-3) 05/26/2017 04:24:06 PM
RNN News: Current Report Filing (8-k) 05/05/2017 04:32:02 PM
RNN News: Securities Registration: Employee Benefit Plan (s-8) 05/03/2017 04:40:29 PM
RNN News: Quarterly Report (10-q) 05/03/2017 04:30:30 PM
RNN News: Current Report Filing (8-k) 04/13/2017 04:35:16 PM
PostSubject
#3347  Sticky Note Repost - Updated pipeline chart, as you can DorianGray 03/27/17 11:44:15 PM
#3664   Could be partially attributed to an analyst cutting mypekeispooped 05/27/17 02:32:58 PM
#3663   Slick sucked dropped an S3 in the AH Lone Wolf 05/26/17 04:51:55 PM
#3662   RNN buy 4.04 stocktrademan 05/26/17 11:06:18 AM
#3661   6/4/17 RX-3117 phase 2A data. If data is good no shorts 05/24/17 11:57:02 AM
#3660   This is a 15 dollar stock as each pearsby09 05/20/17 09:39:46 AM
#3659   Gaining momentum now. Looks like 4 should be no shorts 05/19/17 12:09:02 PM
#3658   What a Buy right now! 5 catalysts pearsby09 05/18/17 11:08:22 AM
#3657   Going green today imo no shorts 05/18/17 10:37:09 AM
#3656   * * $RNN Video Chart 05-12-17 * * ClayTrader 05/12/17 04:24:21 PM
#3655   It was a good ride beambe 05/12/17 03:11:39 PM
#3654   100% Agreement beambe 05/12/17 01:38:25 PM
#3653   Many know this is a 10 dollar stock pearsby09 05/12/17 01:34:38 PM
#3652   HUGE volume day pre split would =20 mill WOW ttubular 05/12/17 01:22:54 PM
#3651   Just a little Patience beambe 05/12/17 01:13:43 PM
#3650   Volume: 1,875,289 @ 12:48:26 PM ET beambe 05/12/17 01:06:19 PM
#3649   https://www.maxblue.de/maerkte-analysen/boersen-kurse/aktiendetailseite.prognose beambe 05/12/17 01:03:24 PM
#3648   I agree with all point, but I'm also Lone Wolf 05/12/17 12:54:52 PM
#3647   Looking strong. no shorts 05/12/17 12:39:08 PM
#3646   good VOLUME beambe 05/12/17 12:37:39 PM
#3645   Don't get caught on the Head Fakes! pearsby09 05/12/17 11:55:11 AM
#3644   May be getting out before the upcoming meeting. BLUEVOODU 05/12/17 10:33:16 AM
#3643   Presplit volume =10 mill + how Rnn go ttubular 05/12/17 10:11:23 AM
#3642   Not sure why peeps were selling / shorting Lone Wolf 05/12/17 10:04:26 AM
#3641   Already at yesterday's volume in first 30 minutes no shorts 05/12/17 09:59:09 AM
#3640   Got in on the dip. Let's see what's no shorts 05/12/17 09:56:06 AM
#3639   Been saying...the next low-floater to fly!! ala Lone Wolf 05/12/17 09:53:34 AM
#3638   Yup!! $RNN Boomage in effect!! Lone Wolf 05/12/17 09:52:10 AM
#3637   Flying now no shorts 05/12/17 09:50:54 AM
#3636   Here comes the volume!! With the float Lone Wolf 05/12/17 09:33:43 AM
#3635   $5 holla!! It's comin!! $RNN Lone Wolf 05/12/17 08:11:53 AM
#3634   You are right! n3m3sis 05/12/17 06:02:51 AM
#3633   * * $RNN Video Chart 05-11-17 * * ClayTrader 05/11/17 05:03:06 PM
#3632   Hopefully that's the case. BLUEVOODU 05/11/17 04:43:37 PM
#3631   I don't think that will happen. This pearsby09 05/11/17 04:37:53 PM
#3630   Big day tomorrow ! DJ2NAZTY 05/11/17 04:24:09 PM
#3629   Well lookie lookie: Lone Wolf 05/11/17 04:23:28 PM
#3628   Hate when that happens. Think this has Lone Wolf 05/11/17 04:21:37 PM
#3627   Agreed... just a tad frustrated by buys didn't fire. BLUEVOODU 05/11/17 03:53:43 PM
#3626   It's a great squeeze play. The Lone Wolf 05/11/17 03:44:39 PM
#3625   This is only 30% of the run that pearsby09 05/11/17 03:39:47 PM
#3624   I couldn't get my buys to fire the BLUEVOODU 05/11/17 12:38:48 PM
#3623   This stock has a lot of cash and pearsby09 05/11/17 11:26:27 AM
#3622   Looking good for the bounce and catalyst.. awesome Tdash 05/11/17 11:14:05 AM
#3621   What a beautiful chart!!...and nice, tight float!! $RNN Lone Wolf 05/11/17 11:05:02 AM
#3620   4 Catalysts on their way. The pearsby09 05/10/17 03:37:11 PM
#3619   I Could be wrong... but I wouldn't be BLUEVOODU 05/10/17 10:10:44 AM
#3618   Not entirely sure what that means? BLUEVOODU 05/10/17 09:47:19 AM
#3617   Funny how the 'best ask' sits at that Lone Wolf 05/10/17 08:54:23 AM
#3616   Buss here in the 'Twitter-verse' appears to be Lone Wolf 05/10/17 06:15:51 AM
#3615   Nah...just shorts shirting. Not so unusual after Lone Wolf 05/10/17 06:04:29 AM
PostSubject